Compass-logo-RGB-outlines.png
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
December 01, 2022 08:30 ET | Compass Therapeutics
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and neck, as well as melanomaIn the first part of this Phase 1b study, CTX-471 was dosed as...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 08:00 ET | Compass Therapeutics
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 09:00 ET | Compass Therapeutics
Study site initiations in the United States for a randomized Phase 2/3 study of CTX-009 with paclitaxel in patients with Biliary Tract Cancers (BTC) and a Phase 2 of CTX-009 in patients with...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at Upcoming Investment Conferences
November 08, 2022 08:00 ET | Compass Therapeutics
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces $80 Million Private Placement
November 02, 2022 09:06 ET | Compass Therapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
October 11, 2022 08:00 ET | Compass Therapeutics
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
September 09, 2022 08:00 ET | Compass Therapeutics
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET | Compass Therapeutics
BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 01, 2022 08:00 ET | Compass Therapeutics
Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A Phase 2 trial of CTX-009 as a monotherapy in...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
May 31, 2022 08:00 ET | Compass Therapeutics
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...